Alnylam Q2 2025 rev. $672 mln, up 64% YoY, raises TTR guidance to $2.175 bln-$2.275 bln.

• Alnylam Q2 2025 net product revenues: $672 million (64% growth YoY) • TTR revenues: $544 million (77% growth YoY) • ATTR-CM patients on AMVUTTRA: approximately 1,400 as of June 30, 2025 • AMVUTTRA approvals in EU, Brazil, UK, and Japan • TRITON-CM Phase 3 trial initiated for Nucresiran in ATTR-CM patients • 2025 TTR franchise net revenue guidance raised to $2.175-$2.275 billion

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported robust financial results for the second quarter of 2025, with net product revenues of $672 million, representing a 64% year-over-year (YoY) growth. The company's Total TTR (transthyretin) revenues reached $544 million, marking a 77% YoY increase, driven primarily by the sales of AMVUTTRA (vutrisiran). As of June 30, 2025, approximately 1,400 ATTR-CM (transthyretin amyloid cardiomyopathy) patients were on AMVUTTRA [1].

The quarter saw significant regulatory approvals for AMVUTTRA, with the drug receiving approvals in the European Union, Brazil, the United Kingdom, and Japan [1]. Additionally, Alnylam initiated the TRITON-CM Phase 3 trial of nucresiran in ATTR-CM patients, further solidifying its pipeline in the field [1].

Looking ahead, Alnylam has raised its 2025 TTR franchise net revenue guidance to $2.175-$2.275 billion, reflecting the company's strong performance and expectations for continued growth [1]. This increase underscores Alnylam's commitment to delivering innovative medicines and expanding its patient access efforts.

References:
[1] https://seekingalpha.com/news/4475460-alnylam-pharmaceuticals-non-gaap-eps-of-0_32-beats-by-0_17-revenue-of-773_6m-beats-by-111_15m
[2] https://www.statnews.com/2025/07/31/alnylam-amvuttra-attr-cm-earnings/
[3] https://www.stocktitan.net/news/ALNY/alnylam-pharmaceuticals-reports-second-quarter-2025-financial-5ifqzxu227sz.html